(2S,5R,8S,11S,20S)-20-Amino-2,5-bis-(4-amino-butyl)-8-carbamoylmethyl-3,6,9,14,21-pentaoxo-1,4,7,10,15-pentaaza-cyclohenicosane-11-carboxylic acid

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (2S,5R,8S,11S,20S)-20-Amino-2,5-bis-(4-amino-butyl)-8-carbamoylmethyl-3,6,9,14,21-pentaoxo-1,4,7,10,15-pentaaza-cyclohenicosane-11-carboxylic acid
• 英文别名: (2S,5R,8S,11S,20S)-20-amino-2,5-bis(4-aminobutyl)-8-(2-amino-2-oxo-ethyl)-3,6,9,14,21-pentaoxo-1,4,7,10,15-pentazacyclohenicosane-11-carboxylic acid；(2S,5R,8S,11S,20S)-20-amino-2,5-bis(4-aminobutyl)-8-(2-amino-2-oxoethyl)-3,6,9,14,21-pentaoxo-1,4,7,10,15-pentazacyclohenicosane-11-carboxylic acid
• 化学式: C₂₇H₄₉N₉O₈
• 分子量: 627.742
• InChiKey: HJONSQLIFGKXNA-KNJMJIDISA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -6.3
• 重原子数：
  44
• 可旋转键数：
  11
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.74
• 拓扑面积：
  304
• 氢给体数：
  10
• 氢受体数：
  11

反应信息

• 作为产物：
  描述：

  Fmoc-N-三苯甲基-L-天冬酰胺 、 Fmoc-D-Lys(Boc)-OH 、 (S)-2-(((9H-fluoren-9-yl)methoxy)carbonylamino)-6-pivalamidohexanoic acid 、 Fmoc-Glu(ODmab)-OH 、 alkaline earth salt of/the/ methylsulfuric acid 生成 (2S,5R,8S,11S,20S)-20-Amino-2,5-bis-(4-amino-butyl)-8-carbamoylmethyl-3,6,9,14,21-pentaoxo-1,4,7,10,15-pentaaza-cyclohenicosane-11-carboxylic acid
  参考文献：
  名称：

  Design, synthesis, and biological activity of a cyclic peptide: An inhibitor of HIV-1 tat–TAR interactions in human cells

  摘要：

  Replication of human immunodeficiency virus type 1 (HIV-1) requires specific interactions of Tat protein with the transactivation responsive region (TAR) RNA, a 59-base stem-loop structure located at the 5'-end of all HIV mRNAs. A number of cyclic peptides are known to possess antibiotic activity and increased biological stability. Here we report the design, synthesis, and biological activity of a cyclic peptide (2), which inhibits transcriptional activation by Tat protein in human cells with an IC50 of approximate to 40 nM. Cyclic peptides that can target specific RNA structures provide a new class of small molecules that can be used to control cellular processes involving RNA-protein interactions in vivo. (C) 2000 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(00)00140-2